Protocol Ledger

NCT06899126 · Phase III · RECRUITING

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT06899126 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-24 Enrollment: 686 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06899126
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)686 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06899126
Protocol FieldVerified Registry Value
NCT IdentifierNCT06899126
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment686 participants (ESTIMATED)
Registered Start Date2025-10-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06899126
Hospital Research SiteLocationSite Profile
Providence Medical FoundationSanta Rosa, CAOpen Hospital Dossier ->
Holy Cross HospitalFort Lauderdale, FLOpen Hospital Dossier ->
Cleveland Clinic FloridaWeston, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI